Article

Vision-Ease buys Thailand factory

Vision-Ease Lens (VEL), a designer, manufacturer, and distributor of ophthalmic lenses, is purchasing a cast resin factory in Bangkok, Thailand, from Indelor Lens Co. Ltd. (INDO). The companies expect to finalized the transaction in June after governmental approvals and other conditions to closing are satisfied.

Ramsey, MN-Vision-Ease Lens (VEL), a designer, manufacturer, and distributor of ophthalmic lenses, is purchasing a cast resin factory in Bangkok, Thailand, from Indelor Lens Co. Ltd. (INDO). The companies expect to finalize the transaction in June after governmental approvals and other conditions to closing are satisfied.

VEL officials said that the company is buying the plant to expand its ability to manufacture advanced technology and specialty cast resin products. The factory also will continue to manufacture and supply existing proprietary lenses to INDO.

“Having additional manufacturing capability and space is crucial to maintaining supply and quickly introducing new technologies to our customers as we continue to expand our premium polarized, photochromic, and progressive offerings into new materials that our customers demand,” said Douglas Hepper, chief executive officer of VEL.

The casting facility, built in 2004 to European standards, has more than 40,000 square feet of manufacturing space. VEL officials said that the company plans to keep the plant’s current employees and will integrate existing operations with VEL engineering, quality, and manufacturing processes. The acquisition of the Thai facility will not alter production at either of the company’s existing polycarbonate and glass manufacturing operations in Ramsey, MN, and Jakarta, Indonesia, according to VEL.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.